Western Diet on Cardiometabolic and Immune Function
WD
Effects of a 10-day Western Diet on Cardiometabolic and Immune Function in Midlife Adults
2 other identifiers
interventional
20
1 country
1
Brief Summary
This study will implement a Western Diet (WD) to understand cardiometabolic and immune function in middle-aged adults (50- 64 years old). Vascular health, intestinal permeability, and T-cell function will be examined before, during, and after the WD. The WD is a 10-day diet and will consist of 25% of total energy from added sugars.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2024
CompletedStudy Start
First participant enrolled
July 17, 2024
CompletedFirst Posted
Study publicly available on registry
July 30, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
July 30, 2024
July 1, 2024
2 years
July 8, 2024
July 29, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
Change in Mean Arterial Blood Pressure (mmHg)
Comparison between before, during and after western diet
Over the course of 1-2 months
Change in relative brachial artery flow-mediated dilation (%)
Comparison between before, during and after western diet
Over the course of 1-2 months
Change in absolute brachial artery flow-mediated dilation (mm)
Comparison between before, during and after western diet
Over the course of 1-2 months
Change in T-cell mitochondria respiration (oxygen consumption rate)
Comparison between before, during and after western diet
Over the course of 1-2 months
Change in T-cell flow cytometry (%)
Comparison between before, during and after western diet
Over the course of 1-2 months
Change in intestinal permeability (lactulose : mannitol test)
Comparison between before, during and after western diet
Over the course of 1-2 months
Change in triglycerides (mg/dL)
Comparison between before, during and after western diet
Over the course of 1-2 months
Change in cholesterol (mg/dL)
Comparison between before, during and after western diet
Over the course of 1-2 months
Study Arms (1)
Western Diet
EXPERIMENTALConsumption of 10 days of a diet high in added sugars (25% of total caloric intake)
Interventions
Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
Eligibility Criteria
You may qualify if:
- ability to provide informed consent
- men and postmenopausal women aged 50-64 years
- systolic blood pressure \< 130 mmHg; diastolic blood pressure \< 90 mmHg
- body mass index (BMI) \<30 kg/m2 and % body fat \< 25% for men and \< 33% for women
- fasting triglycerides \< 200 mg/dl (\< 2.3 mmol/L)
- low density lipoprotein (LDL) cholesterol \<160 mg/dl (4.14 mmol/L)
- fasting plasma glucose \<126 mg/dl (\<7.0 mmol/L)
- weight stable in the prior 6 months (≤ 2 kg weight change)
- blood chemistries indicative of normal liver enzymes and renal function (estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) prediction equation must be \>60 ml/min/1.73 m\^2)
You may not qualify if:
- current use of medications or supplements known to lower blood triglycerides or cholesterol (e.g., fibrates, statins, high dose niacin, high dose omega-3 supplement)
- chronic clinical diseases (e.g., coronary artery/peripheral artery/cerebrovascular diseases, heart failure, diabetes, chronic kidney disease requiring dialysis, neurological or autoimmune conditions affecting cognition (e.g. Alzheimer's disease or other forms of dementia, Parkinson's disease, epilepsy, multiple sclerosis, large vessel infarct)
- major psychiatric disorder (e.g. schizophrenia, bipolar disorder)
- current or past (i.e., last 3 months) use of anti-hypertensive or other cardiovascular-acting medications known to influence vascular function and/or arterial stiffness
- current medication use likely to affect central nervous system (CNS) functions (e.g. long active benzodiazepines)
- concussion within last 2 years and ≥ 3 lifetime concussions
- heavy alcohol consumption (≥8 drinks/week for women and ≥15 drinks/week for men)
- recent major change in health status within the previous 6 months (i.e., surgery, significant infection, or illness)
- current smoking within the past 3 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Delaware
Newark, Delaware, 19713, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher Martens, Ph.D.
University of Delaware
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 8, 2024
First Posted
July 30, 2024
Study Start
July 17, 2024
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
July 1, 2027
Last Updated
July 30, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share